Zobrazeno 1 - 10
of 102
pro vyhledávání: ''
Autor:
Ring, A., Battisti, N.M.L., Reed, M.W.R., Herbert, E., Morgan, J.L., Bradburn, M., Walters, S.J., Collins, K.A., Ward, S.E., Holmes, G.R., Burton, Maria, Lifford, K., Edwards, A., Robinson, T.G., Martin, C., Chater, T., Pemberton, K.J., Brennan, A., Cheung, K.L., Todd, A., Audisio, R.A., Wright, J., Simcock, R., Green, T., Revell, D., Gath, J., Horgan, K., Holcombe, C., Winter, M.C., Naik, J., Parmeshwar, R., Gosney, M.A., Hatton, M.Q., Thompson, A.M., Wyld, L., Collins, K., Ward, S., Holmes, G., Morgan, J., Walters, S., Burton, M., Brain, K., Robinson, T., Pemberton, K., Shrestha, A., Nettleship, A., Richards, P., Harder, H., Audisio, R., Murray, C., Thomson, A.M., Gosney, M., Hatton, M., Armitage, F., Patnick, J., Revill, D., Winter, M.
Publikováno v:
British Journal of Cancer
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed056944ecd27827ab3bd963813fe40
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
Autor:
Masako Sato, Hidetoshi Kawaguchi, Satoshi Morita, Makiko Mizutani, Yoshie Hasegawa, Ken-ichi Watanabe, Yasuaki Sagara, Fumikata Hara, Takashi Morimoto, Takahiro Nakayama, Norikazu Masuda, Mitsuya Itoh, Shoichiro Ohtani, Nobuki Matsunami, Kenji Higaki, Masato Takahashi, Tetsuhiro Yoshinami
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. Methods Patients with metastatic breast cancer (MBC) treated with both anthracycline and
Publikováno v:
British Journal of Cancer
Background: The aim of the present study was to investigate whether changes in the tissue expression of human epididymisspecific protein 4 (HE4) could predict therapy resistance and relapse after progestin hormone therapy for medium- and low-risk end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1f3dad813f940e895ecaa2529bb25e
https://hdl.handle.net/10037/24981
https://hdl.handle.net/10037/24981
Publikováno v:
Supportive Care in Cancer
Purpose Pneumatic compression devices (PCDs) are used in the home setting as adjunctive treatment for lymphedema after acute treatment in a clinical setting. PCDs range in complexity from simple to technologically advanced. The objective of this pros
Autor:
I.A.M. Mandjes, Esther H. Lips, Bas B. Koolen, Lennart Mulder, Sjoerd Rodenhuis, Jelle Wesseling, L. Wessels, J. J. de Ronde
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Intrinsic subtypes are widely accepted for the classification of breast cancer. Lacking gene expression data, surrogate classifications based on immunohistochemistry (IHC) have been proposed. A recent St. Gallen consensus meeting recommends to use th
Autor:
Lisa Vandermeer, Stan Z. Gertler, Nathaniel Bouganim, John Hilton, Roanne J. Segal, Daylily S. Ooi, Mark Clemons, G. Dranitsaris, Gregory R. Pond, Susan Dent, Iryna Kuchuk, Eitan Amir, Xinni Song, Sasha Mazzarello, Sean Hopkins, Christina L. Addison
Publikováno v:
Breast Cancer Research and Treatment
The optimal frequency of intravenous (IV) bisphosphonate administration is unclear. We thus performed a study evaluating the effects of switching from 3–4 to 12 weekly therapy in patients with biochemically defined low-risk bone metastases. Patient
Autor:
Oumar Camara, Carola Rabenstein, Cornelia Jörke, Klaus Hoeffken, Ingo B. Runnebaum, Katharina Pachmann, Anne Egbe, U. Hammer
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 135(4):643-647
In breast cancers, the gene for the growth factor receptor HER2 can be amplified leading to increased aggressiveness and metastasis formation. The monoclonal antibody trastuzumab prolongs relapse-free survival highly significantly but eventually many
Autor:
Tianfeng Wang, Ai-ping Lu, Yiqiang Liu, Yijun Zhou, Zhaoqing Fan, Tao Ouyang, Yuntao Xie, Jinfeng Li, Yingjian He
Publikováno v:
Breast Cancer Research and Treatment
This study aimed to compare the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer. Five-hundred and one patients with clinical stage I-III invasive breast cancer were randomly assig
Autor:
M E, Cazzaniga, L, Cortesi, A, Ferzi, L, Scaltriti, F, Cicchiello, M, Ciccarese, S, Della Torre, F, Villa, M, Giordano, C, Verusio, M, Nicolini, A R, Gambaro, L, Zanlorenzi, E, Biraghi, L, Legramandi, E, Rulli, Valter, Torri
Publikováno v:
Breast Cancer Research and Treatment
Purpose: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm thes
Publikováno v:
Breast Cancer Research and Treatment
Mammary gland morphology and physiology are supported by an underlying cellular differentiation hierarchy. Molecular features associated with particular cell types along this hierarchy may contribute to the biological and clinical heterogeneity obser